Memantine Therapy for Multiple Sclerosis
Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis
What it found
The trial ended early for another reason (see below).
Reason given: Unexpected side-effects: reversible and mild to moderate neurological impairment
What was tested
Treatment tested
- Memantine
Placebo
- Placebo
What it measured
Main measures
to assess the efficacy of Memantine in improving memory deficit in MS patients using the SRT scale
6 months
Thinking and memory
Other measures (1)
1. tests for attention (PASAT3, SDMT, Stroop), executive (Raven, MATTIS) and memory (10/36, SRT), quality of life (SF36), and fatigue (Krupp). 2. attention evoked potentials 3. clinical course, disability (EDSS, MSFC, MSSS).
6 months
Disability progressionMyelin repairThinking and memoryFatigueQuality of life (reported by participants)
Who could take part
MS (type not specified) · 18 to 65
Show the full criteria
Inclusion criteria
* Patients with MS (McDonald 2002), both sex, age between 18 to 60 years old, all MS subtypes (RR, SP, PP, PR), stable. * Patients with severe cognitive impairment defined as performing 1.5 SD below control group (matched by age and education) in 2 o more subtests based in our previous study (Sepulcre 2006):
Exclusion criteria
* Psychiatric diseases (Cummings) depression (Hamilton >8), drug or alcohol abuse, benzodiazepine therapy or other medical diseases.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the efficacy of Memantine in improving the cognitive impairment in patients with Multiple Sclerosis (MS)
Papers
Results
Memantine induces reversible neurologic impairment in patients with MS.Neurology · 2009
Background
Sepulcre J, Vanotti S, Hernandez R, Sandoval G, Caceres F, Garcea O, Villoslada P. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult Scler. 2006 Apr;12(2):187-95. doi: 10.1191/1352458506ms1258oa.
Loading reviews and guidelines…
Related trials
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiot
Phase 3 · Not yet recruiting
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Me
Phase 3 · Stopped early
Stopped
- Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinica
Phase 3 · Completed
Missed its main goal
- Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Ther
Phase 3 · Stopped early
Stopped
History
Started
Sept 2007
Main results due
Mar 2008
Finished
Mar 2008